Filings with the U.S. Securities Exchange Commission (SEC)
In accordance with SEC regulations, Genelabs and certain other persons
file reports related to Genelabs that are available on the SEC's EDGAR
online database. The EDGAR database includes the following filings on
Genelabs: annual reports on form 10-K, quarterly reports on form 10-Q,
current reports on form 8-K, proxy statements and “Section 16” reports
by directors and executive officers on their holdings and transactions
of Genelabs' stock. Click on the links below to see these documents.
Company SEC filings on EDGAR
Section 16 filings on EDGAR
Cautionary Language Regarding Forward-Looking Statements
Materials in this website may contain information that includes or is
based upon forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking statements
give our expectations or forecasts of future events. You can identify
these statements by the fact that they do not relate strictly to
historical or current facts. They may use words such as "anticipate,"
"estimate," "expect," "project," "intend," "plan," "believe," and other
words and terms of similar meaning in connection with a discussion of
future operating or financial performance. In particular, these include
statements relating to future actions, research, clinical trials,
prospective products or product approvals, future performance or results
of current and anticipated products, sales efforts, expenses, the
outcome of contingencies such as legal proceedings, and financial
results. Any or all of our forward-looking statements here or in other
publications may turn out to be wrong. They can be affected by
inaccurate assumptions or by known or unknown risks and uncertainties.
Many factors will be important in determining our actual future results.
Our actual results may vary materially, and there are no guarantees
about the performance of Genelabs stock.
We undertake no obligation to correct or update any forward-looking
statements, whether as a result of new information, future events or
otherwise. You should consult any further disclosures we make in our
reports to the SEC. In particular, you should read the section entitled
"Risk Factors" in our most recent 10-K report to the SEC, as it may be
updated in our subsequent 10-Q and 8-K reports. Other factors besides
those listed there could also adversely affect Genelabs.
© Genelabs Technologies, Inc. All rights reserved. -